Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Urogenital Neoplasms 1Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 145Gemcitabine 141Oxaliplatin 135Capecitabine 133Leucovorin 107Irinotecan 99Bevacizumab 92Cetuximab 69Cisplatin 67pembrolizumab 61Radiotherapy 60Nivolumab 41130-nm albumin-bound paclitaxel 41Sorafenib 39Docetaxel 34Albumin-Bound Paclitaxel 31Radiosurgery 28Paclitaxel 27Surgical Procedures, Operative 25regorafenib 24Erlotinib Hydrochloride 23Panitumumab 22Cyclophosphamide 21Celecoxib 20Trastuzumab 19Radiation 18Neoadjuvant Therapy 18IFL protocol 18atezolizumab 17Carboplatin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × National Cancer Institute (U.S.) × Gastrointestinal × Clear all
NCT03480152 2020-06-02

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
5 enrolled 11 charts
DermatologicGastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡